Literature DB >> 7516535

Schistosoma mansoni: immunolocalization of two different fucose-containing carbohydrate epitopes.

B Köster1, M Strand.   

Abstract

We have used two monoclonal antibodies, 128C3/3 and 504B1, to immunolocalize their carbohydrate epitopes in different developmental stages of Schistosoma mansoni. Both epitopes contain fucose: mAb 128C3/3, as we have shown previously, recognizes fucose in a novel, possibly internal linkage (Levery et al. 1992) while mAb 504B1, as we show here, bound to the Le(x) epitope, which contains fucose alpha 1-->3 linked to N-acetyl-glucosamine. The tissue expression of these epitopes was strikingly different and both elicit an immune response in infected hosts. The mAb 128C3/3-defined epitope was exposed on the surface of all larval stages but not on adult worms; however, it was found in the excretory system of adult worms of both sexes. In contrast, surface expression of the Le(x) epitope was initiated after the transformation of cercariae to schistosomula and was maintained throughout the adult life in both sexes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516535     DOI: 10.1017/s0031182000075995

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  11 in total

1.  Immunoelectron microscopical localization of a circulating antigen in the excretory system of Schistosoma mansoni. Ultrastructural localization studies of the excretory system of S. mansoni.

Authors:  J J Bogers; H A Nibbeling; E A Van Marck; A M Deelder
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

2.  Regulation of schistosome egg granuloma formation: host-soluble L-selectin enters tissue-trapped eggs and binds to carbohydrate antigens on surface membranes of miracidia.

Authors:  R El Ridi; P Velupillai; D A Harn
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

3.  Development and characterization of a specific IgG monoclonal antibody toward the Lewis x antigen using splenocytes of Schistosoma mansoni-infected mice.

Authors:  Msano Mandalasi; Nelum Dorabawila; David F Smith; Jamie Heimburg-Molinaro; Richard D Cummings; A Kwame Nyame
Journal:  Glycobiology       Date:  2013-03-29       Impact factor: 4.313

Review 4.  Schistosome glycoconjugates in host-parasite interplay.

Authors:  C H Hokke; A M Deelder
Journal:  Glycoconj J       Date:  2001-08       Impact factor: 2.916

5.  Dendritic cells activated by an anti-inflammatory agent induce CD4(+) T helper type 2 responses without impairing CD8(+) memory and effector cytotoxic T-lymphocyte responses.

Authors:  Yang Wang; Akram A Da'Dara; Paul G Thomas; Donald A Harn
Journal:  Immunology       Date:  2009-11-16       Impact factor: 7.397

6.  Role of adult worm antigen-specific immunoglobulin E in acquired immunity to Schistosoma mansoni infection in baboons.

Authors:  M Nyindo; T M Kariuki; P W Mola; I O Farah; L Elson; R E Blanton; C L King
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

7.  Lacto-N-fucopentaose III (Lewis x), a target of the antibody response in mice vaccinated with irradiated cercariae of Schistosoma mansoni.

Authors:  D Richter; R N Incani; D A Harn
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

8.  Schistosoma mansoni α1,3-fucosyltransferase-F generates the Lewis X antigen.

Authors:  Megan L Mickum; Teerapat Rojsajjakul; Ying Yu; Richard D Cummings
Journal:  Glycobiology       Date:  2015-11-17       Impact factor: 4.313

9.  P selectins and immunological profiles in HCV and Schistosoma mansoni induced chronic liver disease.

Authors:  Mahmoud M Kamel; Shawky A Fouad; Maha M A Basyoni
Journal:  BMC Gastroenterol       Date:  2014-07-28       Impact factor: 3.067

10.  Changes in surface glycosylation and glycocalyx shedding in Trichobilharzia regenti (Schistosomatidae) during the transformation of cercaria to schistosomulum.

Authors:  Jana Řimnáčová; Libor Mikeš; Libuše Turjanicová; Jana Bulantová; Petr Horák
Journal:  PLoS One       Date:  2017-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.